As legalization of cannabis increases worldwide, vaping cannabis is gaining popularity due to the belief that it is less harmful than smoking cannabis. However, the safety of cannabis vaping remains untested. To address this, we developed a physiologically relevant method for in vitro assessment of cannabis vapor on alveolar epithelial cell cultures. We compared the transcriptional response in three in vitro models of cannabis vapor exposure using A549 epithelial cells in submerged culture, pseudo-air liquid interface (ALI) culture, and ALI culture coupled with the expoCube™ advanced exposure system. Baseline gene expression in ALI-maintained A549 cells showed higher expression of type 2 alveolar epithelial (AEC2) genes related to surfactant production, ion movement, and barrier integrity. Acute exposure to cannabis vapor significantly affected gene expression in AEC2 cells belonging to pathways related to cancer, oxidative stress, and the immune response without being associated with a DNA damage response. This study identifies potential risks of cannabis vaping and underscores the need for further exploration into its respiratory health implications.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11890392PMC
http://dx.doi.org/10.1007/s10565-025-09997-3DOI Listing

Publication Analysis

Top Keywords

cannabis vapor
16
alveolar epithelial
12
cannabis
9
oxidative stress
8
vapor alveolar
8
epithelial cells
8
cannabis vaping
8
ali culture
8
gene expression
8
transcriptomic changes
4

Similar Publications

Synthetic cannabinoids (SCs) are novel psychoactive substances (NPS) that are highly potent and associated with a range of severe toxicities. SC use, which is common in UK prisons and homeless communities, typically involves combustion of SC-soaked herb or paper material. Recently, e-cigarettes (or vapes) have emerged as popular delivery vehicles for SCs, and consumption among the general population has risen significantly.

View Article and Find Full Text PDF

As legalization of cannabis increases worldwide, vaping cannabis is gaining popularity due to the belief that it is less harmful than smoking cannabis. However, the safety of cannabis vaping remains untested. To address this, we developed a physiologically relevant method for in vitro assessment of cannabis vapor on alveolar epithelial cell cultures.

View Article and Find Full Text PDF

Design considerations for medicinal cannabis clinical trials in people receiving palliative care.

J Pain Symptom Manage

February 2025

South West Sydney Clinical Campuses, Faculty of Medicine and Health, University of New South Wales (UNSW), NSW, 2170, Australia; Improving Palliative, Aged and Chronic Care through Clinical Research and Translation (IMPACCT), Faculty of Health, University of Technology Sydney, NSW, 2007, Australia; Ingham Institute of Applied Medical Research, Sydney, NSW, 2170, Australia; South West Sydney Local Health District (SWSLHD), Sydney, NSW, Australia. Electronic address:

Context: Evaluating medicinal cannabis in clinical trials is important for informing its efficacy and safety in clinical care. Alongside the inherent practical challenges of conducting clinical trials in people receiving palliative care, operationalising clinical trials with a medicinal cannabis product requires additional consideration of legal, regulatory, ethical, feasibility, pharmacological and product requirements.

Objective: This manuscript aims to explore these considerations when operationalising medicinal cannabis clinical trials in people receiving palliative care.

View Article and Find Full Text PDF

Introduction: As the medically prescribed use of cannabis flower continues to increase, there is a need to understand how vaporized cannabis can acutely affect driving-related skills and risk-taking behaviors in medicinal populations.

Method: Given this, the present study examined the acute effects of vaporized cannabis flower on measures of hazard perception, driving-related risk-taking behaviors, and subjective perceptions of driving skills in a sample of adult medicinal cannabis patients. Participants (N = 38, M age = 43) attended both a baseline (no cannabis) and intervention appointment (with cannabis consumption), where they completed video-based tasks and self-report measures of driving ability.

View Article and Find Full Text PDF

Objective: Despite increasing use of medical cannabis to manage cancer-related symptoms, U.S. payers do not reimburse medical cannabis, leaving patients responsible for all associated costs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!